Form 4: Galectin Therapeutics Director, Richard A. Zordani Jr., Acquires Shares
SEC Form 4 Filing
Director Richard A. Zordani Jr. purchased 1,000 shares of Galectin Therapeutics Inc. on April 30, 2024.
Summary
- On April 30, 2024, Richard A. Zordani Jr., a director of Galectin Therapeutics Inc., acquired 1,000 shares of common stock at a price of $3.52 per share.
- These shares are held indirectly as UTMA custodian for a minor child.
- Following the transaction, Mr. Zordani directly owns 29,583 shares and indirectly owns 1,000 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine transaction, but insider buying can be interpreted as a slightly positive signal.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The purchase could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 04/30/2024 | Date of transaction: Richard A. Zordani Jr. purchased 1,000 shares of Galectin Therapeutics Inc. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.